PMID- 37534207
OWN - NLM
STAT- MEDLINE
DCOM- 20230804
LR  - 20230804
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - The efficacy and safety in radioactive iodine refractory thyroid cancer patients 
      treated with sorafenib.
PG  - 1200932
LID - 10.3389/fendo.2023.1200932 [doi]
LID - 1200932
AB  - BACKGROUND: Sorafenib included in Chinese medical insurance is the earliest 
      targeted drug for radioactive iodine refractory differentiated thyroid cancer 
      (RR-DTC). This study is to further demonstrate the clinical efficacy and safety 
      of sorafenib used in Zhujiang Hospital of Southern Medical University. METHODS: 
      RR-DTC patients treated at our Department of Nuclear Medicine in Zhujiang 
      Hospital of Southern Medical University (October 2017-May 2020) were 
      retrospectively analyzed. Treatment effects, progression-free survival (PFS), and 
      adverse effects (AEs) during medication were evaluated. RESULTS: Of the 31 
      patients included, 26 patients were evaluated for efficacy with a median 
      follow-up time of 17.5 months (4.0-51.0 months). The disease control rate (DCR) 
      was 57.7% (n = 15) and the objective response rate (ORR) was 26.9% (n = 7). Most 
      patients with disease control had thyroglobulin decreases of more than 60% (p = 
      0.004), ORRs were favorable in patients with lung metastasis and lung-only 
      metastasis (p = 0.010 and 0.001, respectively). The PFS of the 26 patients 
      analyzed was 16.5 months (95%CI: 14.41 -23.90 months). In the subgroup analysis, 
      female, patients with lung-only metastasis, hand-foot skin syndrome (HFS), and 
      thyroglobulin response >/= 60% observed longer PFS (p = 0.038, 0.045, 0.035, and 
      0.000, respectively), while patients with bone metastasis had lower PFS (p = 
      0.035). The most common toxicity profile was HFS (93.5%), followed by diarrhea 
      (83.9%), alopecia (74.2%). All the side effects were mainly grade 1-2. Grade 3-4 
      adverse reactions were more common in diarrhea and HFS. CONCLUSIONS: Sorafenib 
      has promising efficacy in RR-DTC, especially in patients with lung metastasis and 
      lung-only metastasis. The AEs of sorafenib were generally mild, and the main AE 
      was HFS.
CI  - Copyright (c) 2023 Ling, Xiong, Luo, Zou, Chen, Pan, Long, Feng and Ouyang.
FAU - Ling, Yuanna
AU  - Ling Y
AD  - Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, China.
FAU - Xiong, Xiaoli
AU  - Xiong X
AD  - Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, China.
FAU - Luo, Jiaxin
AU  - Luo J
AD  - Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, China.
FAU - Zou, Quanliang
AU  - Zou Q
AD  - Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, China.
FAU - Chen, Pan
AU  - Chen P
AD  - Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, China.
FAU - Pan, Liqin
AU  - Pan L
AD  - Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, China.
FAU - Long, Man
AU  - Long M
AD  - Department of Ultrasound Medicine, Zhujiang Hospital, Southern Medical 
      University, Guangzhou, Guangdong, China.
FAU - Feng, Huijuan
AU  - Feng H
AD  - Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, China.
FAU - Ouyang, Wei
AU  - Ouyang W
AD  - Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, Guangdong, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230718
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - 9010-34-8 (Thyroglobulin)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
SB  - IM
MH  - Humans
MH  - Female
MH  - Sorafenib/adverse effects
MH  - *Thyroid Neoplasms/drug therapy/radiotherapy/chemically induced
MH  - Thyroglobulin
MH  - Iodine Radioisotopes/adverse effects
MH  - *Antineoplastic Agents/adverse effects
MH  - Retrospective Studies
MH  - Phenylurea Compounds/adverse effects
MH  - Diarrhea
MH  - *Adenocarcinoma/drug therapy
PMC - PMC10393119
OTO - NOTNLM
OT  - differentiated thyroid cancer
OT  - efficacy and safety
OT  - radioactive iodine refractory
OT  - real-world clinical study
OT  - sorafenib
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/03 06:43
MHDA- 2023/08/04 06:43
PMCR- 2023/01/01
CRDT- 2023/08/03 04:24
PHST- 2023/04/05 00:00 [received]
PHST- 2023/06/28 00:00 [accepted]
PHST- 2023/08/04 06:43 [medline]
PHST- 2023/08/03 06:43 [pubmed]
PHST- 2023/08/03 04:24 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1200932 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jul 18;14:1200932. doi: 
      10.3389/fendo.2023.1200932. eCollection 2023.